{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T22:36:30Z","timestamp":1784846190493,"version":"3.55.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004028","name":"Jiangnan University","doi-asserted-by":"publisher","award":["YJY202302"],"award-info":[{"award-number":["YJY202302"]}],"id":[{"id":"10.13039\/501100004028","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijrobp.2025.09.022","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T22:21:49Z","timestamp":1758579709000},"page":"541-551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Noninvasive Imaging of Claudin 18.2 Expression in Gastric Adenocarcinoma: Synthesis, Preclinical Evaluation, and Preliminary Clinical Study of a Novel [89Zr]Zr-DFO-NY005 Immuno-Positron Emission Tomography Tracer"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3228-7336","authenticated-orcid":false,"given":"Jialiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kequan","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanpeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitian","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.09.022_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0002","article-title":"Trends of gastric cancer burdens attributable to risk factors in China from 2000 to 2050","volume":"44","author":"He","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0003","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/cncr.34511","article-title":"Gastric cancer incidence trends in China and Japan from 1990 to 2019: Disentangling age-period-cohort patterns","volume":"129","author":"Li","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0004","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1016\/S2214-109X(18)30127-X","article-title":"Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries","volume":"6","author":"Zeng","year":"2018","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0005","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0006","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41575-022-00703-w","article-title":"Current developments in gastric cancer: From molecular profiling to treatment strategy","volume":"20","author":"Alsina","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0007","doi-asserted-by":"crossref","DOI":"10.4028\/b-XDTcg5","article-title":"A CLDN18.2-targeted nanoplatform manipulates magnetic hyperthermia spatiotemporally for synergistic immunotherapy in gastric cancer","volume":"12","author":"Wang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0008","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12916-022-02421-1","article-title":"Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer","volume":"20","author":"Jia","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0009","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0010","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","article-title":"Claudin 18.2 as a novel therapeutic target","volume":"21","author":"Nakayama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0011","article-title":"Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0012","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus capox in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: The randomized, phase 3 glow trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0013","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1053\/j.gastro.2018.08.041","article-title":"Loss of tight junction protein claudin 18 promotes progressive neoplasia development in mouse stomach","volume":"155","author":"Hagen","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0014","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1172\/JCI90429","article-title":"Claudin-18-mediated yap activity regulates lung stem and progenitor cell homeostasis and tumorigenesis","volume":"128","author":"Zhou","year":"2018","journal-title":"J Clin Investig"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0015","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canlet.2017.05.033","article-title":"Claudin-18 coupled with EGFR\/ERK signaling contributes to the malignant potentials of bile duct cancer","volume":"403","author":"Takasawa","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0016","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-017-0473-4","article-title":"Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer","volume":"10","author":"Singh","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0017","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12876-023-02924-y","article-title":"CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0018","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00259-023-06561-1","article-title":"[177Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models","volume":"51","author":"Zeng","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0019","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3390\/cancers16030679","article-title":"Claudin 18.2 as a new biomarker in gastric cancer-what should we know?","volume":"16","author":"Mathias-Machado","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.885424","article-title":"Development of a humanized vhh based recombinant antibody targeting claudin 18.2 positive cancers","volume":"13","author":"Zhong","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0021","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2967\/jnumed.120.258467","article-title":"68Ga-DOTA-FAPI-04 PET\/MR in the evaluation of gastric carcinomas: Comparison with 18F-FDG PET\/CT","volume":"63","author":"Qin","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0022","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1007\/s00259-024-06808-5","article-title":"Synthesis, preclinical evaluation and pilot clinical translation of [68Ga]Ga-PMD22, a novel nanobody PET probe targeting CLDN18.2 of gastrointestinal cancer","volume":"51","author":"Wang","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0023","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1021\/acs.chemrev.9b00738","article-title":"Immunopet: Concept, design, and applications","volume":"120","author":"Wei","year":"2020","journal-title":"Chem Rev"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0024","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1007\/s00259-021-05329-9","article-title":"ImmunoPET of CD38 with a radiolabeled nanobody: Promising for clinical translation","volume":"48","author":"Shi","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0025","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1158\/1078-0432.CCR-22-1547","article-title":"ImmunoPET imaging with 89Zr-labeled atezolizumab enables in vivo evaluation of PD-l1 in tumorgraft models of renal cell carcinoma","volume":"28","author":"Mulgaonkar","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-073925","article-title":"Determinants of gastric cancer screening attendance in southeastern china: A cross-sectional study","volume":"13","author":"Huang","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0027","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","article-title":"Gastric cancer treatment: Recent progress and future perspectives","volume":"16","author":"Guan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0028","first-page":"264","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0029","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41591-021-01233-9","article-title":"Intratumoral heterogeneity in cancer progression and response to immunotherapy","volume":"27","author":"Vitale","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0030","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1007\/s00330-025-11430-6","article-title":"CT radiomics-based intratumoral and intertumoral heterogeneity indicators for prognosis prediction in gastric cancer patients receiving neoadjuvant chemotherapy","volume":"35","author":"Li","year":"2025","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0031","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41392-023-01366-y","article-title":"Molecular and functional imaging in cancer-targeted therapy: Current applications and future directions","volume":"8","author":"Bai","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0032","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41568-023-00576-4","article-title":"Advances in PET imaging of cancer","volume":"23","author":"Schwenck","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0033","doi-asserted-by":"crossref","first-page":"8420","DOI":"10.1038\/s41598-019-44874-0","article-title":"Targeting CLDN18.2 by CD3 bispecific and ADC modalities for the treatments of gastric and pancreatic cancer","volume":"9","author":"Zhu","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0034","doi-asserted-by":"crossref","first-page":"856","DOI":"10.2967\/jnumed.123.267110","article-title":"68Ga-NC-BCH whole-body PET imaging rapidly targets claudin18.2 in lesions in gastrointestinal cancer patients","volume":"65","author":"Qi","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0035","first-page":"64","article-title":"Claudin18.2-targeted cancer theranostics","volume":"13","author":"Zhang","year":"2023","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0036","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1007\/s12094-020-02380-0","article-title":"Prognostic impact of claudin 18.2 in gastric and esophageal adenocarcinomas","volume":"22","author":"Arnold","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0037","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1186\/s12885-025-13940-4","article-title":"Claudin 18.2 expression profile in primary tumors and their ovarian metastases: Implications for targeted therapy","volume":"25","author":"Kim","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0038","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jpha.2023.02.011","article-title":"Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors","volume":"13","author":"Chen","year":"2023","journal-title":"J Pharm Anal"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0039","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00259-023-06234-z","article-title":"First-in-human CLDN18.2 functional diagnostic PET imaging of digestive system neoplasms enables whole-body target mapping and lesion detection","volume":"50","author":"Wang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0040","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1007\/s00259-021-05218-1","article-title":"ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-NB1053","volume":"48","author":"Wang","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0041","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/s44321-024-00059-5","article-title":"ImmunoPET imaging of Trop2 in patients with solid tumours","volume":"16","author":"Huang","year":"2024","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0042","article-title":"CMG901, a claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors","volume":"5","author":"Xu","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0043","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific car T cells in gastrointestinal cancers: Phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0044","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1007\/s00259-022-05739-3","article-title":"Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: A preclinical study","volume":"49","author":"Hu","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0045","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.omto.2022.11.003","article-title":"Development and comparison of 68Ga\/18F\/64Cu-labeled nanobody tracers probing claudin18.2","volume":"27","author":"Wei","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0046","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1021\/acs.molpharmaceut.1c00947","article-title":"Targeting claudin 18.2 using a highly specific antibody enables cancer diagnosis and guided surgery","volume":"19","author":"Zhao","year":"2022","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116134","article-title":"Exploration of radionuclide labeling of a novel scfv-fc fusion protein targeting CLDN18.2 for tumor diagnosis and treatment","volume":"266","author":"Li","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0048","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1021\/acsptsci.3c00165","article-title":"Screening, construction, and preliminary evaluation of CLDN18.2-specific peptides for noninvasive molecular imaging","volume":"6","author":"Wang","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0049","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.3390\/cancers15245742","article-title":"Claudin18.2 in advanced gastric cancer","volume":"15","author":"Inamoto","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0050","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1186\/s12951-024-02900-y","article-title":"Discovery of nanobodies: A comprehensive review of their applications and potential over the past five years","volume":"22","author":"Alexander","year":"2024","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0051","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-2857","article-title":"Abstract 2857: Dr30303, a SMART-VHHBody powered anti-CLDN18.2 VHH-Fc with enhanced ADCC activity for the treatment of gastric and pancreatic cancers","volume":"82","author":"Fang","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0052","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2967\/jnumed.116.177857","article-title":"Preclinical pharmacokinetics and biodistribution studies of 89Zr-labeled pembrolizumab","volume":"58","author":"England","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0053","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.2967\/jnumed.118.223636","article-title":"The impact of fc\u03b3ri binding on immuno-PET","volume":"60","author":"Vivier","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0054","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.7150\/thno.39089","article-title":"The influence of glycans-specific bioconjugation on the fc\u03b3ri binding and in vivo performance of 89Zr-DFO-pertuzumab","volume":"10","author":"Vivier","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0055","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2967\/jnumed.121.262967","article-title":"Optimizing immuno-PET imaging of tumor PD-l1 expression: Pharmacokinetic, biodistribution, and dosimetric comparisons of 89Zr-labeled anti-PD-l1 antibody formats","volume":"63","author":"Bouleau","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0056","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13550-023-01030-0","article-title":"Fc-engineered monoclonal antibodies to reduce off-target liver uptake","volume":"13","author":"Mangeat","year":"2023","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.ijrobp.2025.09.022_bib0057","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11307-021-01652-7","article-title":"ImmunoPET: Harnessing antibodies for imaging immune cells","volume":"24","author":"Wu","year":"2022","journal-title":"Mol Imaging Biol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625062832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625062832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:51:48Z","timestamp":1773179508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625062832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0360301625062832"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.09.022","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Noninvasive Imaging of Claudin 18.2 Expression in Gastric Adenocarcinoma: Synthesis, Preclinical Evaluation, and Preliminary Clinical Study of a Novel [89Zr]Zr-DFO-NY005 Immuno-Positron Emission Tomography Tracer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}